S&P BSE 150 Midcap Index News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Sun TV Network Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Sun TV Network Ltd.
Rating: 3
Author: Motilal Oswal

Keep track of all breaking news and updates on S&P BSE 150 Midcap Index from all sources in a single place.

Load latest

NMDC Ltd.

15 Nov 2025

75.26

-0.61%

Company Update

NMDC Ltd - 526371 - Prices Of Iron Ore W.E.F. 15Th November 2025 - Reg.

BSE India

Prices of Iron Ore w.e.f. 15th November 2025.

pdf

Hero MotoCorp Ltd.

15 Nov 2025

5876.50

1.33%

Hero MotoCorp Shares 'Attractively Valued' At Current Levels Says Motilal Oswal; Rates Stock A 'Buy'

NDTV Profit

Motilal Oswal maintains 'Buy' rating on Hero MotoCorp post steady Q2 numbers; sees 17% upside - Check details

Number of FII/FPI investors increased from 1011 to 1033 in Sep 2025 qtr.

IRB Infrastructure Developers Ltd.

15 Nov 2025

43.96

-0.34%

Company Update

IRB Infrastructure Developers Ltd - 532947 - New Project Win By IRB Infrastructure Trust (TOT-17)

BSE India

Copy of update provided by IRB Infrastructure Trust regarding receipt of LOA for TOT-17

pdf

Sun TV Network Ltd.

15 Nov 2025

559.95

0.16%

Movie segment drives growth; core business remains weak

Neutral: Sun TV Network Ltd.

Motilal Oswal

Sun TV Network (SUNTV) reported a weak 2QFY26, with ad revenue declining 13% YoY amid weak consumer sentiment and cut back in ad spends by FMCG players on linear TV.

Sun TV Network Ltd. is trading below all available SMAs

Indraprastha Gas Ltd.

15 Nov 2025

206.56

-0.97%

A muted quarter, but margins and volumes could see traction over next 12–18 months

Buy: Indraprastha Gas Ltd.

Target

ICICI Securities Limited

Indraprastha Gas (IGL) saw YoY ~17.4%/13.6% dip in Q2FY26 EBITDA/PAT to INR 4.4/INR 3.7bn, below I-Sec’s estimates of INR 5.6/INR 4bn, driven by higher gas cost with a reduction in APM and NWG’s share in Q2.

Indraprastha Gas Ltd. has gained 27.10% in the last 1 Year

Apollo Tyres Ltd.

15 Nov 2025

522.65

-0.03%

Strong operating performance; demand outlook improving

Buy: Apollo Tyres Ltd.

Target

ICICI Securities Limited

Apollo Tyres (APTY)’s Q2FY26 operating performance beat our estimate. Decline in RM basket drove strong margin improvement. Domestic replacement demand is expected to pick pace going ahead.

Number of FII/FPI investors increased from 302 to 313 in Sep 2025 qtr.

Bharat Dynamics Ltd.

15 Nov 2025

1536.80

-1.37%

Strong performance; guides for revenue CAGR of over 30% backed by order book

Hold: Bharat Dynamics Ltd.

Recommendation Target

ICICI Securities Limited

BDL’s Q2FY26 performance beat consensus expectation as EBITDA grew 90% YoY driven by strong sales (+114% YoY). EBITDA margin fell 180bps YoY to 16.3%, implying an adverse product mix (gross margin was lower) and potentially higher R&D expenses (other expenses were higher).

ICICI Securities Limited downgraded Bharat Dynamics Ltd. to Hold with a price target of 1590.0 on 15 Nov, 2025.

Coromandel International Ltd.

14 Nov 2025

2240.70

0.36%

Company Update

Coromandel International Ltd - 506395 - Intimation Under Regulation 31(A)(8) Of SEBI (LODR), 2015

BSE India

Please refer attachment

pdf

Aditya Birla Capital Ltd.

14 Nov 2025

330.65

-0.74%

Company Update

Aditya Birla Capital Ltd - 540691 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And …

BSE India

Aditya Birla Capital Limited has informed the exchange about the Scheme of Amalgamation between its two wholly owned subsidiaries

pdf

Glenmark Pharmaceuticals Ltd.

14 Nov 2025

1840.80

-0.11%

Glenmark Pharmaceuticals Q2 results: Profit jumps 72% to 610.43 cr

Business Standard

Glenmark Pharmaceuticals Ltd on Friday reported a 72.2 per cent jump in consolidated profit after tax at Rs 610.43 crore in the second quarter ended September 2025 on the back of its licensing deal with AbbVie for investigational asset 'ISB 2001'. The company had posted a consolidated profit after tax (PAT) of Rs 354.49 crore in the corresponding period last fiscal, Glenmark Pharmaceuticals Ltd said in a regulatory filing. Consolidated total revenue from operations was at Rs 6,046.87 crore as against Rs 3,433.8 crore in the same period a year ago, it added. Total expenses in the quarter under review were at Rs 3,894.98 crore as against Rs 3,000.64 crore in the same period last fiscal, the company said. "Q2FY26 reflects the steady progress we are making in strengthening Glenmark's scientific and strategic foundation. The AbbVie partnership for ISB 2001, along with the income recognised this quarter, is a significant validation of our scientific strength and enables us to advance the

Glenmark Pharmaceuti.. has an average target of 2086.50 from 5 brokers.

Glenmark Pharma Q2 Results: Profit Surges 72%, Revenue Zooms 76%

NDTV Profit | 14 Nov 2025

S&P BSE 150 Midcap Index PB	5.2
S&P BSE 150 Midcap Index PE	34.9
S&P BSE 150 Midcap Index DIV	0.8
S&P BSE 150 Midcap Index EPS	474.7